PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32249610-1	2020	Metformin, an AMP-activated protein kinase (AMPK) activator, has been shown in previous studies to reduce kidney fibrosis in different models of experimental chronic kidney disease (CKD).	Metformin	0-9	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	14-42	
32249610-1	2020	Metformin, an AMP-activated protein kinase (AMPK) activator, has been shown in previous studies to reduce kidney fibrosis in different models of experimental chronic kidney disease (CKD).	Metformin	0-9	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	44-48	
32249610-9	2020	In addition, treatment with metformin was also able to activate kidney AMPK and therefore improve mitochondrial biogenesis.	Metformin	28-37	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	71-75	
32249610-10	2020	It was concluded that metformin can arrest the progression of established kidney disease in the Nx model, likely via the activation of AMPK.	Metformin	22-31	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	135-139